AstraZeneca Reports Decline In Sales And Profits

BMI View: AstraZeneca's Q310 results reinforce our view that emerging markets will drive industry growth. The company's sales in Western Europe declined by 5.95% in Q310 while sales in the US dropped by 13.12% in the same quarter. Contrastingly, sales in emerging markets posted double-digit growth of 14.05% in Q310.

To read the full article, please choose one of the following options: